Group 1 - The core viewpoint of the article highlights significant stock movements in the Hong Kong and US markets, driven by strategic partnerships, positive financial reports, and market trends [1][2][3][4][5][6][7]. Group 2 - Ocean Group (01991) saw a surge of over 13.3% after announcing a strategic partnership with CONSCIOUSNESS FOUNDATION LTD. to establish a joint venture focused on AI smart hardware, marking a significant step in its AI strategy [1]. - Gaming stocks continued to rise, with Melco International Development (00200) up 5.49% and Sands China (01928) up 3.26%, supported by a 24% year-on-year increase in Macau's gaming revenue for January [1]. - China Energy Storage (02399) increased by over 9.2% following its announcement to acquire 100% of Wuzhong Ruichu Technology for RMB 64 million [2]. - The real estate sector showed recovery, with Sunac China (01918) rising 8.2% as market confidence improved in January [3]. - Gold stocks collectively rose, with China’s gold reserves increasing to 74.19 million ounces, marking a continuous increase for 15 months [4]. - In the US market, Lexin Fintech (LX.US) rose 6.04% amid a broader market rally, with the Dow Jones reaching a historic high of 50,115.67 points [5]. - SpyGlass Pharma (SGP.US) debuted on the US market with a 65% increase, focusing on chronic eye disease treatments [6]. - Bitcoin-related stocks rebounded significantly, with Strategy (MSTR.US) up 26.11% [7].

智通财经APP获悉，周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元， IPO价格为16美元。SpyGlass Pharma 是一家临床后期生物技术公司，专注于开发 用于慢性眼部疾病的 持续药物输送系统，旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品 包括一种将药物输送垫与人工晶状体结合的系统，用于治疗像 开角型青光眼或眼压高 等慢性眼病。这 类治疗目标是提高疗效和患者依从性，与传统每日滴眼药水相比有潜在优势。 ...

周五，SpyGlass Pharma(SGP.US)登陆美股市场，开盘股价暴涨超43%，报23美元，IPO价格为16美元。 SpyGlass Pharma是一家临床后期生物技术公司，专注于开发用于慢性眼部疾病的持续药物输送系统， 旨在通过更长效、可持续的治疗方案改善患者的视力和生活质量。其核心研发产品包括一种将药物输送 垫与人工晶状体结合的系统，用于治疗像开角型青光眼或眼压高等慢性眼病。这类治疗目标是提高疗效 和患者依从性，与传统每日滴眼药水相比有潜在优势。 ...